Diagnologix, Llc

Diagnologix pioneers in cell-processing systems to sort, isolate, and manipulate stem cells, immune cells and circulating tumor cells, in bulk-volume biological fluids (e.g. blood) for research and clinical applications. Diagnologix repurposes the lipid shelled perfluorocarbon-filled microbubble (MB), which has been approved by the FDA as an ultrasound contrast agent, as a self-driving vehicle for cell separation and as a tunable artificial cell for target-cell regulation. Diagnologix has filed two series of world-wide patent applications and has been granted two US patents and 2 international patents in 2019. One current focus is on streamlining the workflow for sorting and expanding the naïve T cells, to overcome clinical bottlenecks of cell processing and production, including CAR-T cell manufacturing. Diagnologix will accomplish a scalable and closed cell manufacturing system (BUBLES), which assembles all cell processing steps including isolation of specific T cell types to subsequent cell activation and expansion in a single unit. This innovation can substantially lower the cost of cell manufacturing and potentially decentralize CAR-T cell production, therefore, to benefit more patients.